Eyenovia (NASDAQ:EYEN) Receives “Neutral” Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Eyenovia (NASDAQ:EYEN) in a research note released on Friday morning,Benzinga reports. The firm currently has a $2.00 target price on the stock.

Eyenovia Trading Down 4.2 %

NASDAQ:EYEN opened at $1.38 on Friday. The company’s 50 day moving average price is $2.66 and its 200-day moving average price is $17.98. Eyenovia has a 52 week low of $1.28 and a 52 week high of $124.80. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.58. The stock has a market cap of $1.92 million, a price-to-earnings ratio of -0.02 and a beta of 1.29.

Institutional Investors Weigh In On Eyenovia

A hedge fund recently raised its stake in Eyenovia stock. Geode Capital Management LLC increased its stake in Eyenovia, Inc. (NASDAQ:EYEN) by 36.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 557,994 shares of the company’s stock after purchasing an additional 149,471 shares during the quarter. Geode Capital Management LLC owned 0.87% of Eyenovia worth $288,000 at the end of the most recent quarter. Institutional investors and hedge funds own 25.84% of the company’s stock.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.